The Daily Ledger

HealthNews

WHO issues new type 1 diabetes guidelines for World Diabetes Day

WHO has published new guidelines on insulin use in adults and its first on type 1 diabetes in children, both aimed at low-resource settings. A separate report asks whether daily pills could widen access to newer drugs.

The Daily Ledger Staff · Updated 4 min read

The World Health Organization (WHO) has published two new guidelines on type 1 diabetes in the days before World Diabetes Day on 14 November: one on insulin use in adults, and one on the care of children and adolescents. Both put the emphasis on places where money, equipment and specialist doctors are scarce. Separately, a report by Al Jazeera looks at whether once-daily pills could widen access to a newer class of drugs used for type 2 diabetes and obesity.

What WHO has published

The following details come from WHO's own publication pages.

Insulin guidance for adults

On 12 November 2026 WHO released a 125-page guideline on insulin use for adults with type 1 diabetes, explicitly covering emergency and humanitarian settings. According to WHO's summary:

  • It strongly recommends intensified insulin therapy with multiple daily injections, with doses adjusted to blood glucose readings.
  • Both human insulin and insulin analogues may be used, but human insulin is preferred because it is generally cheaper.
  • In emergencies, care should be adapted to the local context.
  • The document updates earlier WHO guidance on diagnosis and classification, insulin regimens and delivery methods, and the monitoring of blood glucose, including self-monitoring.

WHO says the guideline supports the global target of universal access to affordable insulin and blood glucose self-monitoring by 2030. It is written mainly for health-care providers, and also for policy-makers, programme managers and humanitarian organisations.

A first guideline for children and adolescents

On 13 November 2026 WHO followed with a 170-page guideline which it describes as its first on diagnosing, managing and following up type 1 diabetes in people up to 19 years old. It forms part of WHO's consolidated guidelines on common childhood illness and focuses on primary and secondary care in resource-limited settings. According to the WHO overview, it covers:

  • initial assessment using urine dipstick testing where blood glucose measurement is not available;
  • insulin types, starting doses, regimens and delivery devices, with individualised glucose targets and monitoring;
  • recognising and managing diabetic ketoacidosis, including in young children, and hypoglycaemia;
  • risk-based screening for diabetic eye and kidney disease.

WHO says the recommendations were developed from systematic reviews and are meant to be usable by non-specialist health workers, with the aim of reducing global inequalities in access and outcomes. The specific doses and thresholds are in the full documents, not in the summaries reviewed for this article.

The wider picture: reported claims on pills and prices

The points below come from a single news report by Al Jazeera, published on 14 November, and concern a different area of treatment: GLP-1 drugs, which are used for type 2 diabetes and obesity rather than as a substitute for insulin in type 1 diabetes.

  • Al Jazeera reports that one in nine people aged 20 to 79 has diabetes, and lists Pakistan as having the highest prevalence, at 31.4%.
  • The market has been dominated by weekly injections such as semaglutide and tirzepatide, the report says, but once-daily pills are arriving. It argues that pills may be cheaper and need less cold-chain storage than injections.
  • On price, the report puts a month of the injectable Mounjaro at about $500 in the United States and about $157 in India, where it is made locally, and says locally made oral semaglutide costs about $18 for 30 days. A photo caption in the report notes that Indian generic versions followed the expiry of a key patent on 20 March 2026.
  • Dr Zakir Alavi, an endocrinologist in Karachi, told Al Jazeera that Pakistan is "a country of contrast", with childhood malnutrition alongside rising obesity.
  • Prof. Rayaz Malik of Weill Cornell Medicine–Qatar told the outlet that once-weekly oral versions are not far off.

The report also carries caveats. It says oral semaglutide is poorly absorbed and has to be taken on an empty stomach, that experts point to few head-to-head trials comparing pills with injections, and that injectables still have the strongest long-term evidence. The suggestion that people in South Asia and the Middle East could benefit most is a forecast that depends on availability and falling prices.

Analysis: two routes to the same problem

This section is analysis. The WHO documents and the Al Jazeera report deal with different conditions and different medicines, but they share a theme: in much of the world the obstacle is less the science than cost, supply and the availability of trained staff. WHO's preference for cheaper human insulin, and its acceptance of urine dipsticks where blood testing is unavailable, are practical responses to that. Whether cheaper pills will do something similar for type 2 diabetes is not yet established.

Readers with diabetes should not change treatment on the basis of news reports and should consult their doctor.

Sources

Written with automated tools from the sources above and published without editor review. Spotted an error? Tell us · Corrections Policy

Report a problem with this story · Copyright & takedown